Hikma Pharmaceuticals plc. ADR  |  OTCPK - Current
52wk high:66.50
52wk low:44.20
PE (ttm):-
Div Rate (ttm):0.44
Yield (ttm):0.89%
Market Cap:-
  • Jul. 28, 2015, 3:42 AM
    • Hikma Pharmaceuticals (OTCPK:HKMPY) will buy Boehringer Ingelheim GmbH’s Roxane business for $2.65B to become the sixth-largest supplier of generic medicines in the U.S.
    • Hikma, which will pay $1.18B in cash and issue 40M new shares to Boehringer, has also agreed to make milestone cash payments of up to $125M.
    Jul. 28, 2015, 3:42 AM
  • Jun. 30, 2015, 10:08 AM
    • Bidders for the U.S. portion of Boehringer Ingelheim's Roxane Labs unit include Hikma Pharmaceuticals (OTCPK:HKMPY), Mallinckrodt (MNK +0.7%) and Perrigo (PRGO +1%). The generics business could fetch as much as $2.2B according to sources close to the matter. A deal could close in a matter of weeks.
    Jun. 30, 2015, 10:08 AM | 3 Comments
  • May 28, 2014, 8:27 AM
    • Hikma Pharmaceuticals (HKMPF) has agreed to buy the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300M, as it attempts to boost its "injected medicine" market share.
    • The company will pay $225M upfront for the assets of Boehringer's Bedford Laboratories and another $75M over the course of five years based on the performance of the drugs.
    May 28, 2014, 8:27 AM
  • Nov. 23, 2011, 1:59 PM

    Aeterna Zentaris (AEZS +1.8%) gains after saying it's signed an exclusive agreement for the registration and marketing of perifosine in the Middle East and North Africa with Hikma Pharmaceuticals (HKMPY.PK).

    Nov. 23, 2011, 1:59 PM